ESR1 and neoplasm: While chemotherapy was administered to almost all women who were ER/PgR−, and endocrine therapy was given to patients with tumors that were clearly endocrine-responsive, the sequence of chemotherapy and endocrine therapy was chosen for the majority of patients with tumor expression of at least one of the two receptors.